Velocity Clinical Research Partners with Palantir to Automate Clinical Trial Payment Reconciliation Using AI
核心洞察
Velocity Clinical Research (搜索) has announced a strategic partnership with Palantir Technologies (搜索) to automate the complex payments reconciliation process in clinical trials using advanced artificial intelligence.
The collaboration integrates Palantir's agentic AI technology with Velocity's proprietary workflows, successfully processing and reconciling customer payment report entries while saving significant time for finance teams.
The automated reconciliation solution transforms months of manual effort into near-instantaneous insights, allowing finance teams to focus on strategic, high-value work instead of administrative tasks.
Velocity Clinical Research (搜索), the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies (搜索) to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence to one of the industry's most persistent administrative challenges.
Addressing a Persistent Industry Challenge
Reconciling invoices and payments in clinical research has long been a fragmented, time-consuming, and error-prone task. Sites often use multiple siloed systems to manage invoices, while sponsors and contract research organizations maintain their own financial systems, creating inconsistency and inefficiency.
Payments, frequently tied to patient visits or performance-based milestones, vary significantly across studies and sites. This variability makes forecasting revenue, managing cash flow, and aligning payments with budgets extremely challenging for finance teams.
AI-Powered Solution Delivers Immediate Results
Velocity and Palantir's automated reconciliation solution integrates Palantir's agentic AI technology with Velocity's proprietary workflows. The application successfully processed and reconciled customer payment report entries, saving Velocity's Finance Collections team a significant amount of time and freeing them up to work on high-value tasks.
"Velocity's partnership with Palantir is one more example of how our size and scale is bringing new types of partnerships and innovation to the clinical trials sector," said Raghu Punnamraju, Chief Technology Officer at Velocity. "Automating the AR reconciliation process is a game-changer for clinical trial sites. Our collaboration turns months of manual effort into near-instantaneous insights, enabling our finance teams to focus on strategic, high-value work instead of wrestling with spreadsheets."
Foundation Built on Previous AI Initiatives
Velocity's journey to address this issue began last year when its technology team piloted generative AI agents to identify missed revenue opportunities, such as unrecorded monitoring visits. This initiative laid the foundation for a broader automation project.
When Palantir approached Velocity to explore life sciences use cases for its advanced AI technology, automating accounts receivable reconciliation quickly emerged as a natural fit. Velocity brought deep clinical operations expertise, while Palantir contributed its industry-leading AI systems and modeling capabilities.
Expanding Automation Across Operations
With financial workflows now automated through this partnership, Velocity is exploring opportunities to expand intelligent automation into other operational areas. The company aims to build a continuously learning financial system that optimizes processes while keeping human experts in the loop, with the ultimate goal of empowering teams to focus on strategic growth and patient-centered outcomes.
The partnership between Velocity and Palantir represents a significant step toward modernizing clinical trial operations and unlocking efficiencies that will benefit sponsors, sites, and, most importantly, patients. With over 70 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing.